Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer

被引：2

作者：

Horne, Ashley ^{[1
,2
]}

Harada, Ken ^{[3
]}

Brown, Katherine D. ^{[1
,4
]}

Chua, Kevin Lee Min ^{[5
]}

MCdonald, Fiona ^{[6
]}

Price, Gareth ^{[1
]}

Putora, Paul Martin ^{[7
,8
]}

Rothwell, Dominic G. ^{[9
]}

Faivre-Finn, Corinne ^{[1
,2
]}

机构：

[1] Univ Manchester, Div Canc Sci, Paterson Bldg,Wilmslow Rd, Manchester M20 4BX, England

[2] Christie NHS Fdn Trust, Dept Radiat Oncol, Manchester, England

[3] Showa Univ Northern Yokohama Hosp, Dept Radiat Oncol, Yokohama, Kanagawa, Japan

[4] Christie Hosp NHS Fdn Trust, Dept Res & Innovat, Manchester, England

[5] Natl Canc Ctr, Div Radiat Oncol, Singapore, Singapore

[6] Royal Marsden Hosp, London, England

[7] Kantonsspital St Gallen, Dept Radiat Oncol, St Gallen, Switzerland

[8] Univ Bern, Dept Radiat Oncol, Inselspital, Bern, Switzerland

[9] Univ Manchester, CR UK Natl Biomarker Ctr, Manchester, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 08期

基金：

英国医学研究理事会;

关键词：

Lung cancer; Personalised medicine; Radio-; therapy; Treatment response biomarkers; ADAPTIVE RADIOTHERAPY; PROGNOSTIC VALUE; TUMOR-CELLS; PHASE-II; RADIOSENSITIVITY; DURVALUMAB; RADIOMICS; DISEASE; PET/CT; NSCLC;

D O I：

10.1016/j.jtho.2024.04.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Owing to major advances in the field of radiation oncology, patients with lung cancer can now receive technically individualized radiotherapy treatments. Nevertheless, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies. Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome. This narrative review discusses some of the current achievements and challenges in the realization of personalized radiotherapy delivery in patients with lung cancer. (c) 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

引用

页码：1164 / 1185

页数：22

共 77 条

[1] Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Alessi, Joao V. V.
Ricciuti, Biagio
Wang, Xinan
Pecci, Federica
Di Federico, Alessandro
Lamberti, Giuseppe
Elkrief, Arielle
Rodig, Scott J. J.
Lebow, Emily S. S.
Eicholz, Jordan E. E.
Thor, Maria
Rimner, Andreas
Schoenfeld, Adam J. J.
Chaft, Jamie E. E.
Johnson, Bruce E. E.
Gomez, Daniel R. R.
Awad, Mark M. M.
Shaverdian, Narek
[J]. NATURE COMMUNICATIONS, 2023, 14 (01)
[2] Hypoxia in Lung Cancer Management: A Translational Approach
Ancel, Julien
Perotin, Jeanne-Marie
Dewolf, Maxime
Launois, Claire
Mulette, Pauline
Nawrocki-Raby, Beatrice
Dalstein, Veronique
Gilles, Christine
Deslee, Gaetan
Polette, Myriam
Dormoy, Valerian
[J]. CANCERS, 2021, 13 (14)
[3] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, Jacqueline V.
Mambetsariev, Isa
Hellyer, Jessica A.
Amini, Arya
Neal, Joel W.
Padda, Sukhmani K.
McCoach, Caroline E.
Riess, Jonathan W.
Cabebe, Elwyn C.
Naidoo, Jarushka
Abuali, Tariq
Salgia, Ravi
Loo Jr, Billy W.
Diehn, Maximilian
Han, Summer S.
Wakelee, Heather A.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
[4] Liquid Biopsies for Molecular Biology-Based Radiotherapy
Blomain, Erik S.
Moding, Everett J.
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (20)
[5] Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli, Andrea
Cerbelli, Bruna
Lionetto, Luana
Zizzari, Ilaria
Salati, Massimiliano
Pisano, Annalinda
Federica, Mazzuca
Simmaco, Maurizio
Nuti, Marianna
Marchetti, Paolo
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
[6] Campus Bio-Medico University, Adaptive radiotherapy in locally advanced Non-Small Cell Lung Cancer (LARTIA Trial) (LARTIA)
[7] Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Chaudhuri, Aadel A.
Chabon, Jacob J.
Lovejoy, Alexander F.
Newman, Aaron M.
Stehr, Henning
Azad, Tej D.
Khodadoust, Michael S.
Esfahani, Mohammad Shahrokh
Liu, Chih Long
Zhou, Li
Scherer, Florian
Kurtz, David M.
Say, Carmen
Carter, Justin N.
Merriott, David J.
Dudley, Jonathan C.
Binkley, Michael S.
Modlin, Leslie
Padda, Sukhmani K.
Gensheimer, Michael F.
West, Robert B.
Shrager, Joseph B.
Neal, Joel W.
Wakelee, Heather A.
Loo, Billy W., Jr.
Alizadeh, Ash A.
Diehn, Maximilian
[J]. CANCER DISCOVERY, 2017, 7 (12) : 1394 - 1403
[8] cfDNA methylome profiling for detection and subtyping of small cell lung cancers
Chemi, Francesca
Pearce, Simon P.
Clipson, Alexandra
Hill, Steven M.
Conway, Alicia-Marie
Richardson, Sophie A.
Kamieniecka, Katarzyna
Caeser, Rebecca
White, Daniel J.
Mohan, Sumitra
Foy, Victoria
Simpson, Kathryn L.
Galvin, Melanie
Frese, Kristopher K.
Priest, Lynsey
Egger, Jacklynn
Kerr, Alastair
Massion, Pierre P.
Poirier, John T.
Brady, Gerard
Blackhall, Fiona
Rothwell, Dominic G.
Rudin, Charles M.
Dive, Caroline
[J]. NATURE CANCER, 2022, 3 (10) : 1260 - +
[9] Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis
Chinniah, Chimbu
Aguarin, Louise
Cheng, Philip
Decesaris, Cristina
Cutillo, Alicia
Berman, Abigail T.
Frick, Melissa
Doucette, Abigail
Cengel, Keith A.
Levin, William
Hahn, Stephen
Dorsey, Jay F.
Simone, Charles B., II
Kao, Gary D.
[J]. CLINICAL LUNG CANCER, 2019, 20 (05) : 384 - +
[10] 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
Cooke, Saskia A.
de Ruysscher, Dirk
Reymen, Bart
Lambrecht, Maarten
Persson, Gitte Fredberg
Faivre-Finn, Corinne
Dieleman, Edith M. T.
Lewensohn, Rolf
Diessen, Judi N. A. van
Sikorska, Karolina
Lalezari, Ferry
Vogel, Wouter
van Elmpt, Wouter
Damen, Eugene M. F.
Sonke, Jan -Jakob
Belderbos, Jose S. A.
[J]. RADIOTHERAPY AND ONCOLOGY, 2023, 181

← 1 2 3 4 5 6 7 8 →